Form 4: HealthEquity Director Robert Selander Executes Stock Options and Sells Shares Under 10b5-1 Plan

Director Robert Selander exercised stock options and sold shares of HealthEquity, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Robert Selander, a director at HealthEquity, Inc., executed stock options to acquire common stock and subsequently sold a portion of those shares.
• The transactions were conducted on October 9, 2024, under a pre-arranged Rule 10b5-1 trading plan adopted on July 9, 2024.
• Selander exercised options to purchase 12,500 shares at $28.68 and 7,500 shares at $21.27.
• He then sold 1,504 shares at an average price of $82.073, 4,171 shares at $83.2683, 75 shares at $83.7667, 752 shares at $82.2744, and 1,748 shares at $83.3381.
• Following these transactions, Selander directly owns 59,719 shares of HealthEquity common stock and 37,500 stock options exercisable at $28.68 and 7,500 stock options exercisable at $21.27.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports routine insider trading activity under a pre-arranged plan. No significant positive or negative implications are immediately apparent.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• While the 10b5-1 plan mitigates insider trading concerns, large sales by insiders can sometimes be perceived negatively by the market.

Future Outlook

There is no specific future outlook provided in this document.

Industry Context

Insider transactions are common and closely watched, especially in the healthcare technology sector. The use of a 10b5-1 plan is a standard practice for executives to manage their stock holdings while avoiding potential insider trading accusations.

Comparison to Industry Standards

• It's common for directors and officers of publicly traded companies, including those in the healthcare technology sector like Teladoc or Cerner (now Oracle Health), to have stock option plans as part of their compensation.
• The use of 10b5-1 trading plans is a standard practice among executives at companies like UnitedHealth Group or CVS Health to manage their stock sales in compliance with insider trading regulations.
• The reported weighted average sale prices are within a normal range for market fluctuations, similar to what might be observed in transactions by insiders at comparable companies such as Veeva Systems or athenahealth.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential dilution from option exercises and the effect of insider sales on market sentiment.

Key Dates